{"product_id":"cgen-vrio-analysis","title":"Compugen Ltd. (CGEN): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Compugen Ltd. (CGEN)'s market position starts here: a concise VRIO analysis that cuts straight to the core of its competitive advantage. We've rigorously tested its key assets against the criteria of Value, Rarity, Inimitability, and Organization to determine its true staying power. The distilled summary within \u0026amp;O4\u0026amp; holds the answer - is this a sustainable lead or a fleeting edge? Read on below to uncover the critical insights that define Compugen Ltd. (CGEN)'s future.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCompugen Ltd. (CGEN) - VRIO Analysis: Unigen™ Predictive Computational Discovery Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at Compugen Ltd. (CGEN) and trying to figure out if their Unigen™ platform is just another biotech tool or a real moat builder. After two decades watching these models, I can tell you the platform is central, but its value is only as good as the clinical assets it spits out. Here is the breakdown based on their late 2025 position.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Pipeline Generation and Financial Backing\u003c\/h3\u003e\n\u003cp\u003eThe Unigen™ platform’s value is clear: it’s the engine that identifies novel drug targets and biological pathways. This isn't theoretical; it directly powers their proprietary candidates. For instance, COM701, an anti-PVRIG antibody, is in a platform trial (MAIA-ovarian) for platinum-sensitive ovarian cancer, with pooled Phase 1 data presented at ESMO 2025 showing a median progression-free survival of \u003cstrong\u003e10.5 months\u003c\/strong\u003e in responding patients. Also, GS-0321, an anti-IL-18 binding protein antibody, is in Phase 1 development under license to Gilead. The platform’s output is monetizable, evidenced by the revenue recognition from the Gilead deal, even though Q3 2025 revenue was only \u003cstrong\u003e$1.9 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on their current financial stability, which supports continued R\u0026amp;D investment in Unigen™: as of September 30, 2025, Compugen Ltd. held \u003cstrong\u003e$86.1 million\u003c\/strong\u003e in cash, with a runway expected to fund operations into \u003cstrong\u003eQ3 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Unique Scientific and Computational Blend\u003c\/h3\u003e\n\u003cp\u003eHonestly, many firms claim AI\/ML in drug discovery now, but Compugen Ltd.'s rarity comes from the specific combination of their deep, established scientific knowledge layered with their proprietary AI\/ML algorithms for target identification. This isn't just off-the-shelf software. They actively enhance it; for example, in February 2025, they announced integrating Ultima Genomics’ UG 100 sequencing technology into Unigen™ to gain new insights on gene structure. This iterative, data-intensive approach is hard to replicate quickly.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: The Proprietary Data Moat\u003c\/h3\u003e\n\u003cp\u003eImitation here is high, but the barrier to entry is steep. It’s not just the algorithms; it’s the years of proprietary biological and clinical data that have trained those models. Replicating that entire data moat, combined with the specialized scientific expertise needed to interpret the output - like the Bin2Niche framework presented at the Single Cell Genomics 2025 Conference - takes significant time and capital. It’s a classic example of a knowledge asset that compounds over time.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Active Pipeline Advancement\u003c\/h3\u003e\n\u003cp\u003eThe platform is definitely organized to deliver. They aren't just building it; they are using it to push assets through the clinic and secure major partnerships. Beyond their wholly-owned COM701, the success of COM902 (the TIGIT component) is seen in AstraZeneca’s rilvegostomig, which is in \u003cstrong\u003eten\u003c\/strong\u003e Phase 3 trials across various cancers. This external validation proves the organization is effectively translating Unigen™ discoveries into high-value, partnered programs. They are defintely using the platform as the core of their strategy, not just a side project.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Assessment\u003c\/h3\u003e\n\u003cp\u003eWhen you map the VRIO dimensions, the conclusion is clear: Unigen™ provides a sustained competitive advantage. It’s valuable, rare in its specific execution, difficult to copy due to the data moat, and the company is clearly organized around leveraging it for clinical and financial milestones. The platform is the foundation of their entire business model, which is a strong indicator of a durable edge in this space.\u003c\/p\u003e\n\u003cp\u003eHere is a quick summary of the assessment:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n    \u003cth\u003eKey Supporting Data (2025 Fiscal Context)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eGenerated COM701 (Phase 1 trial ongoing) and GS-0321 (Phase 1, licensed to Gilead)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eProprietary blend of deep science and specialized AI\/ML algorithms\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eDifficult\/High Cost\u003c\/td\u003e\n    \u003ctd\u003eRequires replicating years of proprietary data and specialized scientific expertise\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eActively advancing pipeline; presented new research at Single Cell Genomics 2025 Conference\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n    \u003ctd\u003ePlatform is the foundation for pipeline generation and partnership value (e.g., AstraZeneca\/Gilead deals)\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCompugen Ltd. (CGEN) - VRIO Analysis: COM701 (Anti-PVRIG) Clinical Asset\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eCOM701 (Anti-PVRIG) Clinical Asset\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: This potential first-in-class antibody is in a randomized platform trial for ovarian cancer, representing a key internal value driver.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe MAIA-ovarian Sub-trial 1 is a double-blind, randomized placebo-controlled trial randomizing 60 patients in a 2:1 ratio to COM701 or placebo.\u003c\/li\u003e\n\u003cli\u003ePooled Phase 1 data in platinum-resistant ovarian cancer showed a median Progression-Free Survival of 10.5 months in patients who derived clinical benefit.\u003c\/li\u003e\n\u003cli\u003eA response greater than 18 months was achieved in a single-agent treated patient in prior Phase 1 studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate. While anti-PVRIG is a novel checkpoint, other companies are pursuing similar novel targets.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate. The specific molecule and its clinical data are unique, but the target class is known.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High. They initiated the platform trial in Q2 2025 and are actively managing its progression.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe first patient was dosed in the MAIA-ovarian trial in July 2025.\u003c\/li\u003e\n\u003cli\u003eThe interim analysis for Sub-trial 1 is now estimated for Q1 2027.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, Compugen had approximately $86.1 million in cash.\u003c\/li\u003e\n\u003cli\u003eCash runway is expected to fund operations into Q3 2027.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses for Q3 2025 were approximately $5.8 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. Value is tied directly to successful clinical data readouts, like the expected interim analysis in Q1 2027.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Component\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCOM701 in MAIA-ovarian platform trial; Median PFS of 10.5 months in subset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eNo (Moderate)\u003c\/td\u003e\n\u003ctd\u003eNovel checkpoint target class pursued by others\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eNo (Moderate)\u003c\/td\u003e\n\u003ctd\u003eSpecific molecule unique, but target class known\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes (High)\u003c\/td\u003e\n\u003ctd\u003eTrial initiated July 2025; Cash runway to Q3 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eCompugen Ltd. (CGEN) - VRIO Analysis: AstraZeneca Rilvegostomig Partnership\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRilvegostomig (derived from COM902) is in ten Phase 3 trials across various cancer indications, including lung, gastrointestinal, and endometrial cancers, managed by AstraZeneca.\u003c\/li\u003e\n\u003cli\u003eThe partnership, initiated in 2018, grants Compugen eligibility for up to an aggregate milestone amount of $200 million in development and regulatory milestones for the first product.\u003c\/li\u003e\n\u003cli\u003eCompugen has received $35.5 million in upfront and milestone payments to date from the collaboration.\u003c\/li\u003e\n\u003cli\u003eEligibility for tiered royalties on future product sales exists.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdvancement of a core asset into ten Phase 3 trials by a partner is statistically rare for a company of Compugen's market capitalization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe specific bispecific structure, incorporating the TIGIT component derived from COM902 with reduced Fc effector function, is not easily replicated.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAstraZeneca is responsible for all research, development, and commercial activities under the agreement.\u003c\/li\u003e\n\u003cli\u003eCompugen's financial position as of Q1 2025 included $103.7 million in cash, providing a runway into 2027.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe commitment to ten Phase 3 trials significantly de-risks the asset's development pathway.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Attribute\u003c\/td\u003e\n\u003ctd\u003eSupporting Data Point\u003c\/td\u003e\n\u003ctd\u003eFinancial\/Statistical Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eNumber of Phase 3 Trials\u003c\/td\u003e\n\u003ctd\u003eTen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eTotal Potential Development\/Regulatory Milestones (First Product)\u003c\/td\u003e\n\u003ctd\u003eUp to $200 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eTotal Milestones Received to Date\u003c\/td\u003e\n\u003ctd\u003e$35.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eAsset Progression Scale\u003c\/td\u003e\n\u003ctd\u003eTen Phase 3 trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eAsset Specificity\u003c\/td\u003e\n\u003ctd\u003eBispecific antibody derived from COM902 with reduced Fc effector function\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003ePartner Responsibility\u003c\/td\u003e\n\u003ctd\u003eAll research, development, and commercial activities\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eCash Position (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e$103.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eCompugen Ltd. (CGEN) - VRIO Analysis: Financial Stability and Runway\n\u003c\/h2\u003e\n\u003cp\u003e\nThe financial stability assessment is anchored by the cash position and the absence of external financing obligations.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong style=\"font-size: 1.1em;\"\u003eFinancial Metrics Snapshot (Latest Reported Dates)\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Equivalents\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$93.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Equivalents\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$86 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025 \/ September 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNo debt\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Operational Runway (No Inflows)\u003c\/td\u003e\n\u003ctd\u003eAs of Q2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eInto 2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.98 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nAs of June 30, 2025, Compugen Ltd. held approximately \u003cstrong\u003e$93.9 million\u003c\/strong\u003e in cash, cash equivalents, short-term bank deposits, and investment in marketable securities. The Company reported having \u003cstrong\u003eno debt\u003c\/strong\u003e. This financial structure provides an expected operational runway extending into \u003cstrong\u003e2027\u003c\/strong\u003e, based on the cash position as of June 30, 2025, and assuming no further cash inflows. The net loss for the second quarter ended June 30, 2025, was approximately \u003cstrong\u003e$7.3 million\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe funding stability, characterized by a multi-year runway funded entirely by existing capital and \u003cstrong\u003eno debt\u003c\/strong\u003e, represents a \u003cstrong\u003emoderate\u003c\/strong\u003e rarity among clinical-stage biotechs, where frequent capital raises or debt financing are common to sustain operations through clinical development phases.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe current financial standing is primarily a result of past strategic financing activities, including capital raises (e.g., ATM proceeds of approximately \u003cstrong\u003e$8.87 million\u003c\/strong\u003e net in Q1 2025) and significant upfront and milestone payments from licensing deals, making it an \u003cstrong\u003elow\u003c\/strong\u003e imitability trait based on current operational execution alone.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe \u003cstrong\u003eHigh\u003c\/strong\u003e organization is demonstrated by the ability to fund internal Research \u0026amp; Development plans, including the COM701 MAIA-ovarian trial and the GS-0321 Phase 1 trial progression, without immediate pressure for equity dilution. This is supported by the potential value embedded in existing partnerships:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nPotential for a total of over \u003cstrong\u003e$1 billion\u003c\/strong\u003e in milestone payments and tiered royalties from partnerships with AstraZeneca (rilvegostomig) and Gilead (GS-0321).\n\u003c\/li\u003e\n\u003cli\u003e\nThe Gilead agreement for GS-0321 includes eligibility for milestone payments up to \u003cstrong\u003e$758 million\u003c\/strong\u003e plus single-digit to low double-digit tiered royalties.\n\u003c\/li\u003e\n\u003cli\u003e\nAstraZeneca's rilvegostomig program includes \u003cstrong\u003eten\u003c\/strong\u003e active Phase 3 trials across lung, gastrointestinal, and endometrial cancers as of the Q2 2025 update.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe financial runway provides a \u003cstrong\u003eTemporary\u003c\/strong\u003e competitive advantage by allowing unhindered progression of key pipeline assets, such as COM701 and GS-0321, through critical milestones without the immediate need to access capital markets, thereby preserving shareholder value.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCompugen Ltd. (CGEN) - VRIO Analysis: GS-0321 (Anti-IL18BP) Licensing Deal\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eGS-0321 (Anti-IL18BP) Licensing Deal Terms Summary\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Component\u003c\/th\u003e\n\u003cth\u003eAmount\/Range\u003c\/th\u003e\n\u003cth\u003eTrigger\/Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$60 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReceived from Gilead Sciences\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNear-Term Milestone Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAchieved upon IND clearance (triggered in 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFuture Milestones (Development, Regulatory, Commercial)\u003c\/td\u003e\n\u003ctd\u003eUp to an additional \u003cstrong\u003e$758 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eContingent on future progress\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Deal Value\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$848 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSum of upfront, near-term, and future milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eSingle-digit to low double-digit\u003c\/strong\u003e tiered\u003c\/td\u003e\n\u003ctd\u003eOn worldwide net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe licensing agreement provides a non-dilutive funding stream to Compugen Ltd. (CGEN).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial funding included an upfront payment of \u003cstrong\u003e$60 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eA milestone payment of \u003cstrong\u003e$30 million\u003c\/strong\u003e was triggered by the FDA clearance of the Investigational New Drug (IND) application in 2024.\u003c\/li\u003e\n\u003cli\u003eCGEN is eligible to receive up to an additional \u003cstrong\u003e$758 million\u003c\/strong\u003e in future development, regulatory, and commercial milestone payments.\u003c\/li\u003e\n\u003cli\u003eThe agreement includes \u003cstrong\u003esingle-digit to low double-digit\u003c\/strong\u003e tiered royalties on worldwide net sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe asset is characterized as a potential \u003cstrong\u003efirst-in-class\u003c\/strong\u003e antibody targeting the IL-18 binding protein pathway.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific financial terms, including milestone amounts and royalty structure, are locked in by the exclusive license agreement with Gilead.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCompugen was responsible for preclinical development and the initiation of the \u003cstrong\u003ePhase 1 trial\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003cstrong\u003ePhase 1 trial\u003c\/strong\u003e for GS-0321 was initiated in the fourth quarter of 2024.\u003c\/li\u003e\n\u003cli\u003eGilead holds the sole right to develop and commercialize GS-0321 thereafter.\u003c\/li\u003e\n\u003cli\u003eThe company reported a cash balance of \u003cstrong\u003e$103.3 million\u003c\/strong\u003e as of December 31, 2024, with a cash runway expected into \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe contract establishes a \u003cstrong\u003esustained\u003c\/strong\u003e, non-operating income stream through defined future milestone payments and royalties.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCompugen Ltd. (CGEN) - VRIO Analysis: Broad Intellectual Property Protection\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eBroad Intellectual Property Protection\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\nValue: Patents, like the US one for COM701 valid until at least \u003cstrong\u003eAugust 2037\u003c\/strong\u003e, protect key combination uses, securing market exclusivity for potential future therapies.\n\u003c\/p\u003e\n\n\u003cp\u003e\nRarity: Moderate. Strong IP is standard, but patents covering specific, high-value triple combinations are valuable.\n\u003c\/p\u003e\n\n\u003cp\u003e\nImitability: High. Patents are legally enforced barriers to entry.\n\u003c\/p\u003e\n\n\u003cp\u003e\nOrganization: High. They actively manage and expand this portfolio, as seen by their recent presentations on computational capabilities informing discovery.\n\u003c\/p\u003e\n\n\u003cp\u003e\nCompetitive Advantage: Sustained. Legal protection is the bedrock of pharma value.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eJurisdiction\u003c\/th\u003e\n\u003cth\u003ePatent Subject\u003c\/th\u003e\n\u003cth\u003eExpected Expiration (Earliest)\u003c\/th\u003e\n\u003cth\u003ePatent Number Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited States (US)\u003c\/td\u003e\n\u003ctd\u003eCOM701 Triple Combination (anti-PD-1 and anti-TIGIT)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAugust 2037\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNo. 11,225,523\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan (JP)\u003c\/td\u003e\n\u003ctd\u003eTriple Combination (anti-PVRIG, TIGIT, PD-1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 2038\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNo. JP7348072B2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEurope (EP)\u003c\/td\u003e\n\u003ctd\u003eAnti-PVRIG Antibodies (Use)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 2036\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNo. 3 653 221\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan (JP)\u003c\/td\u003e\n\u003ctd\u003eCOM701 Composition of Matter and Use\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2036\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNo. 2017-562952\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\nSupporting operational and financial metrics related to IP management and platform:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D expenses for the full year ended December 31, 2024, were approximately \u003cstrong\u003e$24.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company has a cash runway expected to fund operations into \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company has \u003cstrong\u003e74\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003cli\u003eCOM701 is a potential first-in-class anti-PVRIG antibody, and COM902 is a potential best-in-class monoclonal antibody targeting TIGIT.\u003c\/li\u003e\n\u003cli\u003eThe Company is executing a clinical strategy to evaluate the benefit of its chemotherapy-free, triple immunotherapy combination of COM701, COM902, and pembrolizumab.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCompugen Ltd. (CGEN) - VRIO Analysis: Pipeline Differentiation Claims\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Key assets are positioned as 'potential first-in-class' (COM701, GS-0321) or 'best-in-class' (COM902), which attracts premium partnership interest and investor focus.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCOM701, a potential first-in-class anti-PVRIG Fc-reduced antibody, demonstrated a median Progression-Free Survival of \u003cstrong\u003e10.5 months\u003c\/strong\u003e in patients who derived clinical benefit in pooled Phase 1 data for platinum-resistant ovarian cancer.\u003c\/li\u003e\n\u003cli\u003eGS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, is licensed to Gilead and is in Phase 1 development.\u003c\/li\u003e\n\u003cli\u003eCOM902, a potential best-in-class Fc-reduced high affinity anti-TIGIT antibody, has its component used in AstraZeneca's rilvegostomig, which has ten Phase 3 trials ongoing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs claim this, but Compugen has two such assets in Phase 1.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTwo proprietary product candidates, COM701 (anti-PVRIG) and COM902 (anti-TIGIT), are in Phase 1 development.\u003c\/li\u003e\n\u003cli\u003eThe pipeline includes one potential first-in-class in Phase 1 (COM701) and another potential first-in-class in Phase 1 (GS-0321).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The claim is only as good as the underlying science that supports it.\u003c\/p\u003e\n\u003cp\u003eThe differentiation relies on the proprietary computational discovery platform (Unigen™) powered by AI\/ML, which identified the targets.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management consistently frames the pipeline around these differentiating attributes in investor communications.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Expectation\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ3 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFunds operations based on current position.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liquid Resources (as of 6\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$93.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eComprised of $6.5M cash, $58.5M short-term bank deposits, and $28.9M short-term marketable securities.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNo debt\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExcluding regular operating liabilities.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$2.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReflects recognition of payments from the Gilead license agreement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$1.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReflects recognition of payments from Gilead and AstraZeneca license agreements.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Differentiation must be proven in the clinic; it’s a marketing advantage until then.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCOM701 MAIA-ovarian platform trial interim analysis estimated in \u003cstrong\u003eQ1 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCOM701 Sub-trial 1 involves 60 patients randomized 2:1 to COM701 or placebo.\u003c\/li\u003e\n\u003cli\u003eGS-0321 Phase 1 trial recruitment ongoing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCompugen Ltd. (CGEN) - VRIO Analysis: Computational Data Feedback Loop\n\u003c\/h2\u003e\n\u003cp\u003eThe Unigen™ platform's value proposition is intrinsically linked to its ability to ingest and learn from clinical outcomes, creating a dynamic, self-optimizing discovery engine.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue: The outcomes from their preclinical and clinical trials enrich the Unigen™ proprietary knowledgebase, creating a self-improving discovery engine.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe computational platform's output is validated through clinical progression. For instance, data characterizing the outcomes of 60 evaluable patients with platinum resistant ovarian cancer from prior COM701 Phase 1 clinical trials was pooled and presented at ESMO 2025, directly feeding back into the understanding of the PVRIG pathway. Furthermore, the TIGIT component derived from CGEN's COM902 is part of AstraZeneca's rilvegostomig program, which has ten active Phase 3 trials as of Q3 2025, representing a significant external validation and data source.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: High. This closed-loop system, where clinical results directly feed the AI discovery engine, is a sophisticated capability.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe rarity is evidenced by the continuous advancement of multiple distinct targets discovered by the platform into clinical stages, such as COM701 (anti-PVRIG) and GS-0321 (anti-IL18BP) in Phase 1, alongside the advanced partnered bispecific rilvegostomig in Phase 3.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: High. It requires the continuous integration of clinical data back into the proprietary computational infrastructure.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe requirement for continuous, proprietary integration is supported by the ongoing investment in R\u0026amp;D, with Research \u0026amp; Development expenses reported at approximately $5.8 million for the third quarter of 2025. This sustained investment is necessary to maintain the infrastructure capable of processing and learning from complex clinical datasets.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: High. They are presenting research based on this integration at conferences like AGBT 2025.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eOrganizational capacity to leverage this loop is demonstrated by the financial stability to support ongoing R\u0026amp;D and clinical operations, with cash, cash equivalents, and marketable securities reported at approximately $86.1 million as of September 30, 2025, providing a projected cash runway into the third quarter of 2027.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eProgram\/Context\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trial Analysis Size\u003c\/td\u003e\n\u003ctd\u003eCOM701 Pooled Analysis (PROC)\u003c\/td\u003e\n\u003ctd\u003e60 evaluable patients\u003c\/td\u003e\n\u003ctd\u003eESMO 2025 Abstract\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnered Phase 3 Trials\u003c\/td\u003e\n\u003ctd\u003eRilvegostomig (COM902 derived TIGIT component)\u003c\/td\u003e\n\u003ctd\u003eTen active Phase 3 trials\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Update\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenditure\u003c\/td\u003e\n\u003ctd\u003eOperational Cost for Platform Maintenance\/Advancement\u003c\/td\u003e\n\u003ctd\u003e$5.8 million\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Projection\u003c\/td\u003e\n\u003ctd\u003eFunding for Operations\u003c\/td\u003e\n\u003ctd\u003eInto Q3 2027\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained. This learning mechanism compounds over time, widening the gap between them and competitors using static models.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe compounding advantage is reflected in the pipeline depth and the nature of the data presented:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePooled analysis data from three prior COM701 Phase 1 trials informed the design of the ongoing MAIA-ovarian platform trial.\u003c\/li\u003e\n\u003cli\u003eThe platform identified COM701 (anti-PVRIG) and COM902 (anti-TIGIT) as proprietary candidates now in clinical development.\u003c\/li\u003e\n\u003cli\u003eThe platform's output is integrated into a Gilead-licensed program (GS-0321) and an AstraZeneca-partnered program (rilvegostomig).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCompugen Ltd. (CGEN) - VRIO Analysis: Planned Executive Leadership Transition\n\u003c\/h2\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe planned transition in \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e, with the current President and CEO, Dr. Anat Cohen-Dayag (CEO since \u003cstrong\u003e2010\u003c\/strong\u003e), moving to the newly created role of Executive Chair of the Board of Directors, aims to ensure continuity and strategic focus during a critical clinical period. Dr. Eran Ophir, Ph.D., currently Chief Scientific Officer, is appointed President and CEO.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow. Leadership changes are common, but a planned, strategic handover from a long-tenured CEO (since \u003cstrong\u003e2010\u003c\/strong\u003e) is a sign of good governance.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow. It’s an internal organizational decision involving the appointment of the current Chief Scientific Officer to the CEO role.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. The structure is set to maintain momentum, which is crucial given the Q2 \u003cstrong\u003e2025\u003c\/strong\u003e net loss of approximately \u003cstrong\u003e$7.3 million\u003c\/strong\u003e, compared with a net loss of approximately \u003cstrong\u003e$2.1 million\u003c\/strong\u003e in Q2 \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe current organizational structure supports pipeline advancement, as evidenced by recent financial and operational data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eComparison Period\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2024: $2.1 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2024: $6.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPS (Basic\/Diluted)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$0.08\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2024: -$0.02\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (As of June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$93.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpected funding runway into \u003cstrong\u003e2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNo debt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary. Its benefit is realized only if the transition is smooth and the new CEO executes effectively, especially while advancing key pipeline assets.\u003c\/p\u003e\n\n\u003cp\u003ePipeline and Partnership Status:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFirst patient dosed in MAIA-ovarian platform trial for COM701 in platinum-sensitive ovarian cancer in July \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePartner AstraZeneca advancing rilvegostomig program with \u003cstrong\u003eten\u003c\/strong\u003e active Phase 3 trials.\u003c\/li\u003e\n\u003cli\u003eCompugen received a \u003cstrong\u003e$30 million\u003c\/strong\u003e milestone payment from Gilead for GS-0321 (COM503) IND clearance in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnalyst consensus recommendation is \u003cstrong\u003e1.3\u003c\/strong\u003e ('Buy') based on 4 brokerage firms.\u003c\/li\u003e\n\u003cli\u003eAverage one-year analyst price target is \u003cstrong\u003e$4.75\u003c\/strong\u003e, implying an upside of \u003cstrong\u003e259.85%\u003c\/strong\u003e from the \u003cstrong\u003e$1.32\u003c\/strong\u003e price point mentioned in May \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516134088853,"sku":"cgen-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/cgen-vrio-analysis.png?v=1740162477","url":"https:\/\/dcf-model.com\/es\/products\/cgen-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}